Robak, P.; Szemraj, J.; Mikulski, D.; Drozdz, I.; Juszczak, K.; Jarych, D.; Misiewicz, M.; Kościelny, K.; Fendler, W.; Robak, T.
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. J. Clin. Med. 2021, 10, 5028.
https://doi.org/10.3390/jcm10215028
AMA Style
Robak P, Szemraj J, Mikulski D, Drozdz I, Juszczak K, Jarych D, Misiewicz M, Kościelny K, Fendler W, Robak T.
Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of Clinical Medicine. 2021; 10(21):5028.
https://doi.org/10.3390/jcm10215028
Chicago/Turabian Style
Robak, Paweł, Janusz Szemraj, Damian Mikulski, Izabela Drozdz, Karolina Juszczak, Dariusz Jarych, Małgorzata Misiewicz, Kacper Kościelny, Wojciech Fendler, and Tadeusz Robak.
2021. "Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens" Journal of Clinical Medicine 10, no. 21: 5028.
https://doi.org/10.3390/jcm10215028
APA Style
Robak, P., Szemraj, J., Mikulski, D., Drozdz, I., Juszczak, K., Jarych, D., Misiewicz, M., Kościelny, K., Fendler, W., & Robak, T.
(2021). Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Journal of Clinical Medicine, 10(21), 5028.
https://doi.org/10.3390/jcm10215028